Oil and gas explorer and developer McMoRan Exploration Co. (NYSE: MMR) recently said drill results from its Blueberry Hill tested positive for a potential major natural gas discovery.

The deep gas exploratory sidetrack well located on Louisiana State Lease 340 was drilled to a true vertical depth of 21,900 feet, indicating resistive zones approximately 150 gross feet, the New Orleans, La.-based company said. McMoRan plans to deepen the well to a depth of 24,000 feet following a repair of a mechanical issue.

On March 29, 2009, the company reported it re-entered the Blueberry Hill operation with the intent to sidetrack a previously bored well.

“We are extremely encouraged by these drilling results which indicate thickening on the flank of the Blueberry Hill structure and a potential major discovery,” said McMoRan’s co-chairman, James R. Moffett. “We look forward to drilling deeper to evaluate additional prospective sands encountered in the original well. This appears to be a large structure with significant reserve potential and additional development and exploration opportunities.”

McMoRan potentially will add Blueberry Hill to its prior successes, including Flatrock, Hurricane, Hurricane Deep, JB Mountain and Mound Point, with further significant discoveries possible in this important area.

“Like our major discovery at Flatrock, where six wells in the field are currently capable of producing at a gross rate of over 300 million cubic feet of natural gas equivalents per day, Blueberry Hill is another clear example of our deeper pool concept. Blueberry Hill is located approximately 11 miles southeast of Flatrock and represents the deeper expression of the structural features of the shallower Mound Point field, which produced over 2.5 trillion cubic feet of natural gas equivalents from multiple wells above 12,500 feet,” Moffett stated.

McMoRan controls 150,000 acres in OCS Block 310/Louisiana State Lease 340, and has 42.9% working interest and a 29.7% net revenue interest in the Blueberry Hill project, while Plains Exploration and Production Co. (NYSE: PXP) holds a 47.9% working interest.

About McMoRan Exploration

McMoRan engages in the exploration, development and production of oil and natural gas offshore in the Gulf of Mexico and onshore in the Gulf Coast area. The company has one of the largest acreage positions in the shallow waters of the Gulf of Mexico and Gulf Coast areas.

BeaconEquity.com Research Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

The provider of health IT solutions Merge Healthcare (Nasdaq: MRGE) recently announced its unaudited results for the second quarter ended June 30, 2009.

The Milwaukee, Wis.-based company said in a news release the preliminary results for the quarter were made public for the benefit of its shareholders, other interested investors, and shareholders of etrials Worldwide Inc. (Nasdaq: ETWC) who are considering Merge’s tender offer to acquire all registered shares of etrails Worldwide.

In the announcement, Merge Healthcare included operating results for the quarter, as well as an estimated impact to its financial statement as a result of the sale of Merge’s equity interest in Eklin Medical Systems Inc., which is part of the Elkin’s acquisition by VCA Antech Inc. (Nasdaq: WOOF).

Merge Healthcare will receive approximately $1.4 million for its equity share in Eklin from VCA, the acquirer of Eklin, with the bulk of the proceeds to be received during the third quarter of 2009. The transaction will appear in the company’s second-quarter earnings results as a $3.6 million non-cash write down of its interest in Eklin.

The company will also report $2.2 million of non-recurring revenue for the second quarter as a result of a new value added reseller (VAR) agreement that was assigned to VCA by Eklin as part of VCA’s acquisition in June. The VAR may generate additional income in subsequent quarters, the company said.

Merge Healthcare said preliminary unaudited results is for revenue to reach between $15 million and 15.5 million, compared with $13.3 million posted last year during the same period.

Operating income will total from $3.7 million to $4.4 million, up substantially from an operating loss of $18.3 million for the second quarter of fiscal 2008.

Merge Healthcare expects a net profit range of $0.1 million and $0.8 million, up from last year’s second-quarter loss of $18.2 million. Earnings before interest, taxes, depreciation and amortization (EBITDA, which include the amortization of stock-based compensation) will reach from between $3.1 million to $2.4 million, up from a loss of $14.0 million for the same quarter last year. Excluding the non-cash equity impairment charge of $3.6 million, second-quarter EBITDA is expected to reach between $6.7 million and $6.0 million.

The company stated the results are preliminary and subject to change following review by its independent public accounting firm.

About Merge Healthcare

Merge Healthcare develops software solutions that automate healthcare data and diagnostic workflow to create a more comprehensive electronic record of the patient experience. Every Merge product, ranging from standards-based SDKs to fully integrated clinical applications, is built on decades of technology and expertise in medical software development, delivery and support.

BeaconEquity.com Research Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

The developer and maker of medical robotics Hansen Medical Inc. (Nasdaq: HNSN) recently announced preliminary second-quarter revenue revealing a significant plunge below Wall Street’s estimates, citing pullbacks in customer purchase commitments during the deepening global recession, Reuters reported.

The Mountain View, Calif.-based company said some customers required additional approval or alternative financing arrangements before placing orders, pushing purchasing decisions during the quarter into the next quarter.

“Sensei system sales during the second quarter were adversely affected by general macroeconomic conditions that continue to significantly impact our potential customers’ capital spending,” CEO Frederic Moll stated in the press release.

“I was expecting the company to come in weak, I just didn’t know to what degree,” Needham & Co analyst Sameer Harish said.

But Harish said sales for the quarter aren’t as bad as it may appear, as revenue from three systems already shipped will be reported for the third quarter.

The company’s Sensei robotic catheter system positions catheters within the heart more easily and accurately during certain cardiac procedures.

Hansen anticipates revenue for the second quarter to total $3.1 million to $3.3 million, compared with Thomson Reuters estimate of $8.7 million, and $7.1 million in revenue posted in the first quarter.

The company shipped approximately 626 Hansen Artisan catheters in the most recent quarter, compared with approximately 600 during the first quarter, it said.

Hansen provided no further guidance, withdrawing its previous revenue estimates for the remainder of 2009 due to uncertain market conditions.

Audited results for the second quarter will be announced in early to mid-August. The mean analyst estimate polled by Thomson Reuters is for the company to earn 36 cents per share, compared with 61 cents per share on revenue of $5.8 million for the second quarter of fiscal 2008.

About Hansen Medical Inc.

Hansen Medical Inc. develops, manufactures, and markets medical robotics designed for accurate positioning, manipulation, and stable control of catheters and catheter-based technologies.

BeaconEquity.com Research Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

NovaBay’s New Compound to Treat Viral Conjunctivitis

Swiss-based Alcon Inc. (NYSE: ACL) and partner NovaBay Pharmaceuticals (NYSE-AMEX: NBY) of Emeryville, Calif., jointly announced Alcon has begun the phase II clinical trial of NovaBay’s patented lead Aganocide compound, NVC-422, to treat viral conjunctivitis, commonly referred to as “pink eye” or “Madras eye.”  Conjunctivitis is a common ocular disease, described by an inflammation of the conjunctiva (inner surface of the eyelids).  The disease is contagiously transmitted from person to person.

The various causes of conjunctivitis are mostly due to an allergic reaction or an infection, either viral or bacterial, and is responsible for more than 4 million visits to a doctor or hospital in the United States each year.  Millions of other cases go unreported.

The world’s leading eye care company Alcon and drug developer NovaBay Pharmaceuticals partnered in the licensing and research of Alcon’s Aganocide(R) compounds.  These compounds are expected to be used in the eye, ear and sinus, as well as in contact lens solutions.

NovaBay’s Aganocide is a proprietary synthetic analog of the same molecules contained in white blood cells, which are the cells the body naturally uses to attack viruses and bacteria.  NovaBay said Aganocide compounds offer a solution to the problem of rising resistance of microbes the body triggers to fight traditional antibiotics.

Aganocide just successfully completed its phase I study to show safety and tolerability, with the demonstration  of 120 healthy volunteers experiencing no serious adverse effects.

“We are pleased to be entering mid-stage clinical testing for viral conjunctivitis,” said Ron Najafi, Ph.D., chairman and CEO of NovaBay. “This is the first step in the ophthalmic clinical development program for NVC-422, which has the immediate goal of developing the first effective product to address viral conjunctivitis for which there are limited treatment options.”

Phase II will be a multi-center, randomized, placebo-controlled trial to show safety and efficacy of NVC-422 with patients with viral conjunctivitis.  The study will involve 250 patients at more than 30 medical centers.

“This study is an important step forward with the clinical program for this potentially dual-acting therapy to address the multiple causes of conjunctivitis. Dual action against viral and bacterial conjunctivitis is important because when an infection is diagnosed it is difficult, time-consuming and expensive to determine the underlying cause of the infection and treat it properly,” said Dr. Sabri Markabi, M.D., Alcon’s senior vice president of research and development and chief medical officer.

Alcon Laboratories Inc. (NYSE: ACL)
Founded in 1945, Alcon Laboratories Inc. traces its roots back to two pharmacists, Robert Alexander and William Conner, who opened a small pharmacy in Fort Worth, Texas, and combined the first syllables of their last names to create the name Alcon.

Majority owned by Nestlé S.A. and incorporated in Hünenberg, Switzerland with U.S. operations based in Fort Worth, Texas, the company team of over 15,000 dedicated employees worldwide develops, manufactures, and distributes hundreds of eye care products in more than 180 countries.

In March 2002, Alcon conducted a partial initial public offering (IPO) on the New York Stock Exchange (NYSE). Nestlé still owns approximately 75% of the company.

Alcon’s core business is centered on three key divisions – Surgical, Pharmaceutical and Consumer Vision Care. As of 2008, sales reached US$6.3 billion.

Alcon conducts business at offices located in 75 countries around the world in regions including Canada and the Far East; Europe, Middle East and Africa; Latin America and the Caribbean; and the United States.

NovaBay Pharmaceuticals (NYSE-AMEX: NBY)

NovaBay is focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and community environments. Many of these infections have become increasingly difficult to treat because of the rapid increase in infectious microbes that have become resistant to current drugs.
NovaBay’s in vitro and in vivo tests have demonstrated our compounds kill a wide range of bacteria, viruses and other infection causing microbes, including those that are resistant to multiple antibiotics.

It is developing hospital indications and have partnered certain other indications with Alcon, the world’s leading eye care company, and with Galderma S.A., a global leading pharmaceutical company dedicated exclusively to the field of dermatology.

Beacon Equity Disclaimer

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

ZAGG Inc. (OTCBB: ZAGG), maker of specialty electronic accessories, recently announced it has entered into a distribution agreement with Target Corp. (NYSE: TGT) to provide the retailing giant ZAGG’s latest product, invisibleSHIELD(TM), according to TMCNet.

Salt Lake City, Utah-based ZAGG manufactures protective clear coverings and accessories to the consumer electronics industry. InvisibleSHIELD protects personal electronic accessories such as cellphones, digital cameras and laptops from scratches, marks and nicks.

InvisibleSHIELD is made from ultra-strong patented film initially produced for the U.S. Department of Defense to protect helicopters from sand and other debris from damaging the blades, but the company is moving forward to expand its applications.

“Electronics owners who want to protect their gadgets from scratches, but still be able to show them off, will be excited to find the invisibleSHIELD in their favorite Target stores,” Derek Smith, ZAGG’s vice president of sales told TMCNet.

According to ZAGG, the introduction of invisibleSHIELD protection solution is the first of its type in the marketplace, but not the first distribution agreement. The latest distribution agreement with Target comes on the heels of two previous agreements made with large retail chain stores Best Buy and Wal-Mart.

“We associate Target with being very trend-forward and innovative, which is a great match for ZAGG and our award-winning products,” added Robert G. Pedersen II, ZAGG’s president and CEO.

Analysts familiar with company say though margins have narrowed significantly from the shift away from Web site sales to brick-and-mortar distribution, elevated sales volume maintains the company’s earnings growth and shareholder value.

The company also announced the launch this summer of AppSpace.com, a Web site for the handheld applications market.

About ZAGG Inc. (ZAGG)

ZAGG Inc. (ZAGG) designs, manufactures and distribute protective coverings, audio accessories and power solutions for consumer electronic and hand-held devices under the brand names invisibleSHIELD and ZAGGaudio.

The invisibleSHIELD is designed specifically for iPods, laptops, cell phones, digital cameras, personal digital assistants (PDAs), watch faces, global positioning (GPS) systems, gaming devices and other items. ZAGG offers over 3,000 precision pre-cut designs with a lifetime replacement warranty through online channels, big-box retailers, electronics specialty stores, resellers, college bookstores, Mac stores and mall kiosks.

During the year ended December 31, 2008, the ZAGGaudio line of electronics accessories and products was released. The flagship product within ZAGGaudio is Z.buds.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

TechTeam Global Inc. (Nasdaq: TEAM), a worldwide leader and provider of information technology outsourcing and business process outsourcing service, recently announced the launch of its new business unit, Global Life Sciences Business Unit.

In a news release to investors, the company said the formation of the new business unit is a response to growing demand and rapid opportunities in the life sciences industry. The formation of the Global Life Sciences Business Unit dovetails into the company’s previously formed Global Pharmaceutical Center of Excellence, supporting the pharmaceutical unit in its mission to provide services to fill unique needs of the pharmaceutical industry.

The new organization affords the company two important strategic changes, including increased focus and attention at the corporate level, and expands the scope of the operation beyond the pharmaceutical industry to serve the needs of the life sciences industry more broadly.

TechTeam serves clients in more than 500 clinical trials, in 25 languages, and across 25,000 sites, worldwide. The company offers eClinical technology to help clients with linguistics, user and application administration, site assessment, connectivity, solution provisioning, and training.

“Based on the level of customer interest and TechTeam’s unique ability to meet the needs of these customers, we see a tremendous opportunity to continue to grow this global business at an aggressive rate,” said Chris Donohue, the TechTeam corporate vice president who will lead the new business unit. “We have proven capabilities and already support some of the top names in this important industry. We are investing to add capacity, expand capabilities and to increase our visibility in the market.”

TechTeam is no stranger to the life sciences, having served the industry for a decade, but the formation of the Global Life Sciences Business Unit represents a large step in the company’s strategic move to capture one of the fastest growing segments of the world economy. Additionally, the need for research facilities to reduce costs at the product development stage has taken front stage, as companies find investors and underwriters seeking higher returns from capital more at risk in a world economy re-evaluating its increase need for risk-shifting toward technology development in all industries, especially biopharmaceutical and other life sciences.

“We have provided support to customers in the life sciences industry for 10 years,” says Gary J. Cotshott, TechTeam’s president and CEO. “The decision to create the Global Life Sciences Business Unit reflects our deep commitment to this industry, our customers and prospects, and their growing needs.”

“Last year we established a Global Pharmaceutical Center of Excellence. The formation of a full business unit on this foundation is the next logical step in the execution of our growth strategy. Looking to the future, we will continue to work closely with our customers to set priorities and evolve our capabilities in this area,” said Cotshott.

About TechTeam Global Inc.

TechTeam Global Inc. is a leading provider of IT outsourcing and business process outsourcing services to large and medium businesses, as well as government organizations. The company’s primary services include service desk, technical support, desk-side support, security administration, infrastructure management and related professional services.

TechTeam also provides a number of specialized, value-added services in specific vertical markets. Founded in 1979, TechTeam has nearly 3,000 employees across the world, providing IT support in 32 languages. TechTeam’s common stock is traded on the NASDAQ Global Market under the symbol “TEAM.”

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Federal judge says company should give 17 tons of shipwreck treasure back to Spain; Odyssey announces plans to file a written objection to the U.S. Federal Court Magistrate’s recommendation

Odyssey Marine Exploration Inc. (Nasdaq: OMEX) saw its shares nearly halved last week after a federal judge ruled the Florida-based deep-sea explorers should give the 17 tons of shipwreck treasure back to Spain.

According to the report, federal magistrate judge Mark Pizzo ruled the treasure was recovered from the wreck of the Nuestra Senora de las Mercedes and is covered by sovereign immunity – the principle that naval vessels belong to their flag nation regardless of age or location. In an order last week, Pizzo wrote Spain is the rightful owner of the treasure, which was being carried by a Spanish navy galleon when it sank southwest of Portugal in 1804.

Odyssey has been locked in lengthy a battle with Spain over the ownership since it announced the find, popularly known as the “Black Swan” treasure, in May 2007.

The company brought the said case to federal court in the spring of 2007 after discovering the site in the Atlantic Ocean with over 500,000 gold and silver coins. Spain filed a claim in the case asserting the cargo came from the Nuestra Senora de las Mercedes, a Spanish vessel which exploded in 1804.

With the Spanish government hailing the federal judge’s recent decision, Spanish Culture Minister Angeles Gonzalez-Sinde stated, “I am delighted that the judge has ruled that the ship belongs to Spain and the treasure belongs to Spain. It is a very important decision.”

He added the decision set an important precedent.

Odyssey, addressing questions brought by intense international media coverage, made this statement, “Returning the coins to the Spanish Government when they never owned them defies logic and reason. We also disagree with the Magistrate’s apparent assumption that a vessel was found at the site. Furthermore, the Magistrate accepted facts as presented by Spain without giving Odyssey an opportunity to cross examine witnesses at a trial.”

Answering whether the case affects its currents and balance sheet, the company said its shipwreck operations continue to be focused in the “Atlas” search area with both of its ships working in the English Channel. In addition, it said it has been planning additional operations for 2009 in other areas of the world. For its balance sheet, Odyssey said the case does not have any effect, saying the “Black Swan” coins were never treated as assets on their balance sheet.

But determined to win the battle, Odyssey said it will file its objection and will continue to vigorously defend its rights to what it has legally recovered and submitted to the jurisdiction of the court.

Melinda MacConnel, Odyssey’s vice president and general counsel, stated, “This is clearly a case where there are many relevant issues of fact that have been disputed, including the issue of whether the Mercedes was on a commercial mission and whether the property recovered belonged to Spain. I presume that the claimants in the case who assert ownership rights by virtue of the fact that their ancestors owned a portion of the cargo will join us in objecting.”

About Odyssey Marine Exploration Inc.

Odyssey Marine Exploration Inc. is engaged in the exploration of deep-ocean shipwrecks and uses innovative methods and state-of-the-art technology to conduct extensive search and archaeological recovery operations around the world. Odyssey discovered the Civil War era shipwreck of the SS Republic® in 2003 and recovered over 50,000 coins and 14,000 artifacts from the site nearly 1,700 feet deep. In May 2007, the company announced the historic deep-ocean treasure recovery of over 500,000 silver and gold coins, weighing 17 tons, from a Colonial era site code-named “Black Swan.” In February 2009, Odyssey announced the discovery of Balchin’s HMS Victory. The company also has other shipwreck projects in various stages of development around the world.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Analyst report shows a vast amount of carbonates resources on Tamm Oil & Gas’ Manning Project in Peace River, Alberta; findings suggest untapped reserves.

Emerging junior oil and gas exploration and development company Tamm Oil and Gas (OTCBB: TAMO) recently announced that a four-star research analyst recently released an updated report regarding the company’s Manning Project in Peace River, Alberta, showing the presently held and additional acreages acquired by the company contain significant barrels of oil originally in place (OOIP).

Ernest C. Schlotter, a senior analyst with SISM Research and a four-star analyst according to StarMine released an updated report stating the Manning Project in Peace River contains approximately 3.16 billion OOIP.

“The new lands acquired are contiguous to Tamm’s lands already owned and have increased its holding in the world class Manning project by 26%. Based on Chapman’s parameters we calculated the total of heavy oil in place to be 3,158,871,600 [barrels],” Schlotter wrote in the report.

Tamm Oil & Gas lease holdings, including the recently acquired 7,860 acres lease, total more than 30,000 acres. The newly acquired leased land location trends within known significant heavy oil resources, representing large potential of carbonates resources in the Alberta region.

“The Manning Project is within the carbonate trend that is known to host a significant heavy oil resource. The carbonates are the next frontier in the Alberta oil industry,” Schlotter continued. “Like oil sands two decades ago, carbonates represent an enormous and relatively untapped petroleum resource. The prospective heavy oil reserves at Manning, and the indications of deeper conventional oil potential justify an aggressive, continued lease acquisition, coupled with seismic studies and exploration drilling programs by the company.”

Investors cheered with 11 times average volume Friday afternoon at Schlotter’s assessment of Tamm’s value based upon OOIP estimates, as Schlotter concluded, “Currently Tamm is valued at $0.019 per barrel based on our new oil originally in place (OOIP) assessment of 3.15 billion barrels. We believe today’s value for Tamm shares should be $2.75 and long-term share value may reach $10.40.”

About Tamm Oil & Gas (OTCBB: TAMO)

Tamm Oil & Gas Corp (OTCBB: TAMO) is an emerging junior oil and gas exploration and development company based in Calgary, Alberta, Canada. The company plans to add corporate asset value through the drilling and production of petroleum and heavy oil.

Tamm has acquired 47 sections (30,080 acres) of oil and gas rights (Manning Properties) in the Peace River Oil Sands Area of NW Alberta. The company holds a 100% working interest in petroleum, natural gas and heavy oil rights on these lands. Internal company estimates have determined over 3 Billion original barrels of heavy oil in place on the properties within the Mississippian Debolt and Elkton zones. The Tamm lands are also considered to be prospective for conventional light oil and natural gas.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Umbilical cord blood stem cell preservation company Cord Blood America Inc. (OTCBB: CBAI), on its path to being able to operate on its cash flow, recently reported it has reduced its secured debt by a total of $4.194 million in the first five months of 2009.

Two months ago, the company announced it had decreased its debt by $1.75 million this year. Cord Blood America founder and CEO Matthew Schissler, expressing pleasure on how the company is progressing, said decreasing debt would be one of their significant items to focus on in 2009. According to Schissler, eliminating debt makes our financial balance sheet stronger and makes Cord Blood America a better investment.

Since that time, it further reduced its secured debt by $1.627 million and eliminated liquidated damages totaling $817,000.

In a press release, Schissler said the latest announcement shows achievement in debt reduction, which he said is one of the three strong pillars needed to take the company to the next level – the other two are organic growth and acquisition.

Pushing organic growth forward, Schissler said the company’s deferred revenues for the first quarter were up 20 %. For acquisitions, Schissler said the company is in the process of building or buying a stem cell laboratory for increased acquisition capacity and higher gross margin.

Cord Blood America, through its subsidiaries, provides private cord blood stem cell preservation services to families in the United States. According to Research and Markets report, cord blood banking is increasingly being used to improve and save lives. Stem cells derived from umbilical blood have been used in more than 8,000 transplants worldwide to treat a wide range of blood diseases, genetic andmetabolic disorders, immunodeficiencies and various forms of cancer, the report said.

Meanwhile, stem cell research got back into the limelight as President Obama reversed the federal funding ban on the research. Cord Blood America can look forward to strategic growth as bullish signals dominate the biotech sector.

The company also engages in collecting, processing, and preserving peripheral blood and adipose tissue stem cells, which allows individuals to privately preserve their stem cells for potential future use in stem cell therapy.

Schissler said the company’s strategy for 2009 is in place and they stand by their ability to perform and to make all three pillars strong and sturdy.

About Cord Blood America

Cord Blood America (OTCBB: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.

To find out more about Cord Blood America, visit http://www.corcell.com. For investor information, visit http://www.cordblood-america.com.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Company enjoying strong product awareness momentum and investor approval following $15 million sales surge in May

SpongeTech Delivery Systems Inc. (OTCBB: SPNG) announced early Friday morning its receipt of an initial order from wholesale giant Costco. The Costco order for the company’s car care products represents a milestone in its efforts to achieve widespread customer acceptance, as any order made by Costco’s purchasing department passes an important litmus test of professional approval at the mass merchandising level of Costco.

“We look forward to our new relationship with retail giant, Costco,” Steven Moskowitz, chief operating officer of SpongeTech Delivery Systems stated in the press release. “Costco has the geographic coverage, floor traffic and the demographics that are important in delivering our product to the marketplace on a national level. Our business continues to expand rapidly with reorders as well as new purchase orders and SpongeTech’s products will now be more available to the public.”

The Costco order comes on the heels of another important development in the company’s strategy for brand awareness when it announced 14 strategic partnerships in Major League Baseball (MLB) with the Arizona Diamondbacks, Atlanta Braves, Baltimore Orioles, Boston Red Sox, Cincinnati Reds, Cleveland Indians, Chicago Cubs, Colorado Rockies, Houston Astros, Florida Marlins, Los Angeles Angels, Philadelphia Phillies, San Francisco Giants, and the Toronto Blue Jays.

The partnerships serve as a high profile marketing tactic for the company’s care car products, densely targeting its optimum buyer. High-profile permanent outfield signs and home plate rotational signage are included in the partnership agreement with the teams.

In addition, SpongeTech will have outfield wall signage at the MLB All-Star Game and Home Run Derby in St. Louis in 2009, Anaheim in 2010, and Arizona in 2011.

“These deals will enhance our brand and drive recognition among retailers and consumers,” said Moskowitz. “As our business continues to show unprecedented growth, these programs will continue to establish SpongeTech® as a category leader.”

Additional products such as SpongeTech’s new children’s bath sponge will be introduced soon, the company said, and should continue the exponential growth the company plans for branding itself as America’s Cleaning Company™.

SpongeTech designs, produces, markets and distributes cleaning products for vehicular use utilizing technology relating to sponges containing hydrophilic, which are liquid absorbing, foam polyurethane matrices.

The company’s products can be pre-loaded with detergents and waxes, which are absorbed in the core of the sponge then gradually released during use.

The company licenses the rights to manufacture and sell its products from H.H. Brown Shoe Technologies, Inc. (doing business as Dicon Technologies), the holder of the relevant patents relating to the hydrophilic sponges.

The company has designed and Dicon Technologies is conducting research and development for products using the same hydrophilic technology for bath and home use.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity.com is a website wholly-owned by BlueWave Advisors, LLC.  BlueWave Advisors, LLC has been compensated fifty-thousand dollars from Pine Mountain Ventures, a shareholder of SPNG, as a marketing budget to manage a comprehensive investor awareness program including the creation and distribution of this report as well as other investor relations efforts. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.